Definitive Contract HHSO100201300010C
Award Date
6/19/13
Potential Completion Date
6/1/19
Potential Value
$85M
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Switzerland
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Clinger Cohen Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $267,582,260 definitive cost-sharing contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Basilea Pharmaceutica International Ltd, Allschwil, doing business as Basilea Pharmaceutica International SA, Allschwil. The contract supports the development of antimicrobials for the treatment of resistant fungal and bacterial infections, targeting high-priority pathogens such as carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and...
This is a $49,795,199.00 cost-sharing definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Spero Therapeutics, Inc. for the development of SPR994, an oral carbapenem antibiotic for the treatment of drug-resistant Gram-negative bacterial infections. The contract was awarded on July 12, 2018 with a period of performance through October 31, 2026. It was not set aside for any specific business category. The contract originated from a Broad...
<p>This is a federal contract award valued at $237,994,127.86, awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Hoffmann-La Roche Inc. The contract is for the "COMBATING MULTI-DRUG RESISTANCE AND ADDRESSING EMERGING BACTERIAL THREATS: DISCOVERY, CLINICAL DEVEL" program, with a period of performance through September 30, 2027. The contract is a definitive, cost-no-fee contract and does not have a set-aside designation.</p>
This is a $30,704,925.57 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Achaogen, Inc., a for-profit organization. The contract was awarded on September 1, 2008, with a period of performance through August 27, 2016, and was not set aside for any specific business type. The contract was awarded under a Broad Agency Announcement (BAA) solicitation, BAA...
This is a definitive cost-sharing contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to Locus Biosciences Inc., a clinical-stage biopharmaceutical company, for the clinical development of a CRISPR-Cas3 phage cocktail to treat recurrent urinary tract infections caused by Escherichia coli, including antimicrobial and multi-drug resistant strains. The contract has a ceiling value of $91,817,550.73 and a completion...
This is a $27,032,719.27 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Spero Therapeutics, Inc. to advance the clinical and non-clinical development of an antibiotic candidate. The contract is not set aside. The contract originated from a NIAID Broad Agency Announcement (BAA) soliciting proposals for the advanced development of vaccine candidates, therapeutic products, and diagnostics to address biodefense, antimicrobial...
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
This is a $31,943,633.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Crestone, Inc., a for-profit biotechnology company based in Boulder, Colorado. The contract, which has no set-aside designation, is to support the development of novel therapeutic treatments for antibiotic-resistant bacterial infections, including advancing a small-molecule...
This is a $7,621,277 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, Massachusetts. The contract is to develop phenoxyacetamide T3SS inhibitors as adjunctive agents to antibacterial therapy for treating multidrug-resistant Pseudomonas aeruginosa infections. This work was originally solicited through a Broad Agency Announcement seeking proposals to develop...
This is a federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Pattern Bioscience, Inc., a biotechnology company, to develop a rapid pathogen identification and antimicrobial susceptibility testing platform. The contract, valued at $40,937,536.73, is for the verification, clinical evaluation, and U.S. Food and Drug Administration (FDA) clearance of this culture-free, phenotypic diagnostic platform. The contract is a...